The National Cancer Data Base report on patterns of care for testicular carcinoma, 1985-1996

Cancer

Volumn 86, Issue 10, 1999, Pages 2171-2183

  Steele, Graeme S ^a   Richie, Jerome P ^a   Stewart, Andrew K ^b   Menck, Herman R ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b AMERICAN COLLEGE OF SURGEONS   (United States)

Author keywords

National Cancer Data Base; Nonseminoma; Radiation therapy; Seminoma; Surgery; Survival; Testicular carcinoma

Indexed keywords

ADULT; ARTICLE; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DATA ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; PRIORITY JOURNAL; SURVIVAL TIME; TESTIS CANCER; TREATMENT OUTCOME;

EID: 0033570937     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991115)86:10<2171::AID-CNCR42>3.0.CO;2-M     Document Type: Article

References (50)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.
2. Forman D, Oliver RT, Brett AR. Familial testicular cancer: a report of the UK family register, estimation of risk and HLA class sib-pair analysis. Br J Cancer 1992;65:255-62.
3. Nichols CR, Heerema NA, Palmer C, Loehrer PJ, Williams SD, Einhorn LH. Klinefelter's syndrome associated with mediastinal germ cell neoplasms. J Clin Oncol 1987;5:1290-4.
4. Timmerman JM, Northfelt DW, Small EJ. Malignant germ cell tumors in men infected with the immunodeficiency virus: a report of 26 cases. J Clin Oncol 1995;13:2705-11.
5. Daniels JL, Stutzman RE, McCleod DG. A comparison of testicular tumors in white and black patients. J Urol 1981; 125:341-2.
6. Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol 1990;8:1777.
7. Kennedy BJ, Schmidt JD, Winchester DP, Peace BL, Natarajan N, Mettlin C. National survey of patterns of care for testis cancer. Cancer 1987;60:1921-30.
8. Oliver RTD. Clues from the natural history and results of treatment supporting the monoclonal origin of germ cell tumors. Cancer Surv 1990;9:333-68.
9. Loehrer PJ, Johnson D, Elson P, Einhorn LH, Trump D. Importance of bleomycin in favorable prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1995;13:470-6.
10. Levin M. Prognostic features of primary and metastatic testis germ cell tumors. Urol Clin North Am 1993;20:39-53.
11. Richie JP. Clinical stage I testicular cancer: the role of modified retroperitoneal lymph node dissection. J Urol 1990;144: 1160-3.
12. Pechham M, Barrett A, Liew K, Horwich A, Robinson B, Dobbs HJ, et al. The treatment of metastatic germ cell testicular tumors with bleomycin, etoposide and cisplatin (BEP). Br J Cancer 1983;47:613-9.
13. American Joint Committee on Cancer. Beahrs OH, Myers MH, editors. Manual for the staging of cancer. 2nd edition. Philadelphia: J.B. Lippincott, 1983.
14. American Joint Committee on Cancer. Beahrs OH, Henson DE, Hutter RVP, Myers MH, editors. Manual for the staging of cancer. 3rd edition. Philadelphia: J.B. Lippincott, 1988.
15. American Joint Committee on Cancer. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. Manual for the staging of cancer. 4th edition. Philadelphia: J.B. Lippincott, 1992.
16. Jessup JM, Steele GD, Winchester DP. Introduction. In: Steele GD, Jessup JM, Winchester DP, Menck HR, Murphy GP, editors. National Cancer Data Base annual review of patient care, 1995. Atlanta: American Cancer Society, 1995: 1-11.
17. Menck HR, Cunningham MP, Jessup JM, Eyre HJ, Winchester DP, Scott-Conner CEH, et al. The growth and maturation of the National Cancer Data Base. Cancer 1997;80:2296-304.
18. Cancer facts and figures, 1985, 1986, 1990, 1991, 1995, 1996. Atlanta: American Cancer Society, 1985, 1986, 1990, 1991, 1995, 1996.
19. SPSS for Windows. Advanced statistics. Release 6.1. Chicago: SPSS Inc., 1994.
20. Marubini E, Valsecchi MG. Analyzing survival data from clinical trials and observational studies. New York: John Wiley & Sons, 1995.
21. Shambaugh E, Young JL Jr., Zippin C, Lum D, Akers C, Weiss MA. Statistics and epidemiology for cancer registrars. Book 7. Bethesda: National Institutes of Health, 1995.
22. Lee ET. Statistical methods for survival data analysis. Belmont, CA: Wandsworth, Inc., 1960.
23. Percy C, Van Holten V, Muir C, editors. International classification of diseases for oncology, 2nd edition. Geneva: World Health Organization, 1990.
24. Commission on Cancer, American College of Surgeons. Standards of the Commission on Cancer. Volume I: Cancer program standards. Chicago: Commission on Cancer, 1996.
25. Devessa SS, Blot WJ, Stone BJ, Miller BA, Tarone RE, Fraumeni JF Jr. Recent cancer trends in the United States. J Natl Cancer Inst 1995;87:175-82.
26. Bosl GJ, Motzer RJ. Testicular germ cell cancer. N Engl J Med 1997;337:242-53.
27. Steele GS, Richie JR. Current role of retroperitoneal lymph node dissection in testicular cancer. Oncology 1997;2:717-37.
28. Steele GS, Richie JR. Surgery and chemotherapy for advanced nonseminomatous testicular cancer. Curr Opin Urol 1997;7:304-11.
29. Donahue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Primary retroperitoneal lymph node dissection in clinical stage a non-seminomatous germ cell testis cancer. Review of the Indiana University experience, 1965-1989. Br J Urol 1993;71:326-35.
30. Baniel J, Foster RS, Einhorn L. Late relapse of clinical stage I testicular cancer. J Urol 1995;154:1370-5.
31. Krege S, Kalund G, Otto T, Goepel M, Rubben H. Phase II study: adjuvant single-agent carboplatin therapy for clinical stage I seminoma. Eur Urol 1997;31:405-7.
32. Oliver RTD, Edmonds PM, Ong JYH, Ostrowski MJ, Jackson AW, Baille-Johnson H, et al. Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: should it be tested in a randomized trial against radiotherapy? Int J Radiat Oncol Biol Phys 1994;29:3-8.
33. Fiveash J, Sandler HM. Controversies in the management of stage I seminoma. Oncology 1998;12:1203-21.
34. Fossa SD, Aass N, Kaalhuis O. Radiotherapy for testicular seminoma stage I: treatment results and long term post irradiation morbidity in 365 patients. Int J Radiat Oncol Biol Phys 1989;16:383-8.
35. Hanks GE, Peters T, Owen J. Seminoma of the testis: long term beneficial and deleterious results of radiation. Int J Radiat Oncol Biol Phys 1992;24:913-9.
36. Wanderas EH, Fossa SD, Tretli S. Risk of a second germ cell cancer after treatment of a primary germ cell tumor in 2201 Norwegian male patients. Eur J Cancer 1997;33:244-52.
37. Moller H, Mellemgraad A, Jacobsen GK, Pedersen D, Storm HH. Incidence of second primary cancer following testicular cancer. Eur J Cancer 1993;29A:672-6.
38. von der Maase H, Spect L, Jacobsen A, et al. Surveillance following orchiectomy for stage I seminoma of the testis. Eur J Cancer 1993;29A(14):1931-4.
39. Coogan CL, Mohamed JH, Wahle GR, Foster RS, Rowland RG, Bihrle R, et al. Nerve sparing post-chemotherapy retro-peritoneal lymph node dissection for advanced testicular cancer. J Urol 1996;156:1656-8.
40. Whitemore WF Jr. Germinal tumors of the testis. In: Proceedings of the Swedish National Cancer Conference. Philadelphia: J.B. Lippincott Co., 1973:485-99.
41. Donahue JP, Zachary JM, Maynard BR, Distribution of nodal metastases in nonseminomatous testis cancer. J Urol 1982; 128:315-20.
42. Freedman L, Parkinson MC, Jones WG, Oliver RT, Peckham RJ, Mead G, et al. Histopathology in the prediction of relapse of patients with Stage I testicular teratoma treated by orchiectomy alone. Lancet 1987;8554:294-8.
43. Li M, Whitemore W, Golbey R, Grabstaldt H. Effects of combined drug therapy on metastatic cancer of the testis. JAMA 1960;174:1291-9.
44. Rosenbery B, Van Camp L, Krigas T. Inhibition of cell division in E. Coli by electrolysis products from a platinum electrode. Nature 1965;205:698.
45. Samuels ML, Holoye PY, Johnson DE. Bleomycin combination chemotherapy in the management of testicular neoplasia. Cancer 1975;36:318-26.
46. Einhorn LH, Donohue JP. Improved chemotherapy in disseminated testicular cancer. J Urol 1977;117:65-9.
47. Xiao H, Mazumdar M, Bajorin DF, Sarosdy M, Vlamis V, Spicer J, et al. Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. J Clin Oncol 1997;15:2553-8.
48. Stoter G, Sleijfer CTH, Schornagel JH, Bokkel-Huinink WW, Vermeiljen K, Sylvester R. BEP verses VIP in intermediate risk patients with disseminated nonseminomatous testicular cancer (NSTC). Proc Am Soc Clin Oncol 1993;12:714.
49. Einhorn LH, Williams SD, Loehrer PJ, Birch R, Crasga R, Omura G, et al. Evaluation of optimal duration of chemotherapy in favorable prognosis disseminated germ cell tumors: a Southeastern Cancer Group protocol. J Clin Oncol 1998;7:387-91.
50. Skinner DG. Advanced metastatic testicular cancer: the need for reporting results according to initial extent of disease. J Urol 1998;128:312-4.